
    
      Open-label, non-randomized and dose escalation study in which groups of 3-6 patients with
      squamous cell carcinoma of the head and neck will receive sequentially increased dosages of
      azacitidine SC injection in combination with a fixed dose of cisplatin IV injection until
      dose-limiting toxicity is demonstrated in 2 of the 6 patients.
    
  